ClinicalTrials.Veeva

Menu

CP-481,715 Nickel Allergy Study.

Pfizer logo

Pfizer

Status and phase

Completed
Phase 1

Conditions

Dermatitis, Allergic Contact

Treatments

Drug: CP-481,715

Study type

Interventional

Funder types

Industry

Identifiers

NCT00141180
A3081018

Details and patient eligibility

About

To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST.

Exclusion criteria

  • Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding contact allergic dermatitis or untreated, asymptomatic, seasonal allergies at time of dosing).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems